

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

NCT06484868

Status	RECRUITING
Phase	Phase 4
Sponsor	Amryt Pharma
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (1)

- Confirmed diagnosis of familial or acquired partial lipodystrophy

Exclusion (1)

- Treatment with any Investigational Medicinal Product (IMP) within 6 months or 5 times the terminal half-life of the corresponding IMP, whichever is longer, before the screening visit.

Locations (12 total)

Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille, France
Hopital Pitie-Salpetriere, Paris, France
Hôpital Saint-Antoine, Paris, France
... and 9 more locations